Accéder au contenu
Merck
Toutes les photos(1)

Documents

A-020

Supelco

Amobarbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C11H18N2O3
Numéro CAS:
57-43-2
Poids moléculaire :
226.27
Numéro MDL:
MFCD00057558
Code UNSPSC :
41116107
ID de substance PubChem :
329770580
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

SNAP-N-SPIKE®. SNAP-N-SHOOT®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

O=C(NC(C1(CC)CCC(C)C)=O)NC1=O

InChI

1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)

Clé InChI

VIROVYVQCGLCII-UHFFFAOYSA-N

Catégories apparentées

Description générale

A Certified Spiking Solution® for amobarbital testing methods by GC/MS or LC/MS for clinical toxicology, medication monitoring, forensic analysis, pain prescription monitoring, or urine drug testing applications. Amobarbital is a barbiturate approved for treatment of anxiety, insomnia, and epilepsy.

Application



  • Barbiturate biochemical analysis: A study detailed a new approach for the analysis of barbiturates, including amobarbital, using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), highlighting advancements in detecting and quantifying these substances in forensic and toxicological contexts (Wachełko et al., 2023).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Propofol, amobarbital… is it the substance that matters, or the question about the role of the Wada test in brain tumor patients?
Karl Schaller
World neurosurgery, 75(3-4), 428-430 (2011-05-24)
Daniel L Drane et al.
Epilepsia, 53(10), 1790-1798 (2012-07-12)
Exclusive right hemisphere language lateralization is rarely observed in the Wada angiography results of epilepsy surgery patients. Cortical stimulation mapping (CSM) is infrequently performed in such patients, as most undergo nondominant left hemisphere resections, which are presumed not to pose
Julián Carvajal-Castrillón et al.
Revista de neurologia, 55(9), 520-527 (2012-11-01)
An appropriate localization of ictal onset zone in refractory temporal lobe epilepsy favors an adequate outcome associated with surgical treatment. When video-electroencephalogram (video-EEG) and magnetic resonance imaging do not provide accurate data to locate ictal onset zone, the use of
Impact of pretreatment with amobarbital on electroconvulsive therapy outcomes.
Clint Ross et al.
The journal of ECT, 29(1), e10-e11 (2013-02-21)
M Zijlmans et al.
Journal of neurology, 259(8), 1632-1638 (2012-01-27)
The purpose of this study was to evaluate the contribution of posterior circulation to memory function by comparing memory scores between patients with and without a foetal-type posterior cerebral artery (FTP) during the intracarotid amobarbital procedure (IAP) in epilepsy patients.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique